13601-02-0

Basic information

• Product Name: platinum(2+) nitrate ammoniate hydrate (1:2:2:2)
• CAS NO: 13601-02-0
• Molecular Formula: H₁₀N₄O₈Pt
• Molecular Weight: 389.1854
• Mol File: 13601-02-0.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 83°C at 760 mmHg
• Vapor Pressure: 49.8mmHg at 25°C
• CAS DataBase Reference: platinum(2+) nitrate ammoniate hydrate (1:2:2:2)(CAS DataBase Reference)
• NIST Chemistry Reference: platinum(2+) nitrate ammoniate hydrate (1:2:2:2)(13601-02-0)
• EPA Substance Registry System: platinum(2+) nitrate ammoniate hydrate (1:2:2:2)(13601-02-0)

Safety Data

• Hazardous Substances Data: 13601-02-0(Hazardous Substances Data)

Usage

General Description

Platinum(2+) nitrate ammoniate hydrate (1:2:2:2) is a complex chemical compound that consists of platinum(II) ions, nitrate ions, ammonium ions, and water molecules in specific ratios. The chemical formula indicates that for every one platinum(2+) ion, there are two nitrate ions, two ammonium ions, and two water molecules. It is a hydrated complex, meaning it contains water molecules within its structure. platinum(2+) nitrate ammoniate hydrate (1:2:2:2) is often used in chemical research and industrial applications, particularly in metal processing and catalysis. Platinum(2+) nitrate ammoniate hydrate (1:2:2:2) has unique properties and reactivity that make it useful in a variety of chemical processes and reactions.

Upstream product

• 15663-27-1 cisplatin 
• 7732-18-5 water 
• 13841-96-8 cis-diamminediiodoplatinum (II) 
• 26035-31-4 transplatin 

Relevant articles and documents

Improving of Anticancer Activity and Solubility of Cisplatin by Methylglycine and Methyl Amine Ligands Against Human Breast Adenocarcinoma Cell Line

Methylglycine, also known sarcosine, is dramatically used in drug molecules and its metal complexes can interact to DNA and also do cleavage. Hence, to study the influence of methylglycine ligand on biological behavior of metal complexes, two water-solubl

Kinetic and Thermodynamic Investigation of Human Serum Albumin Interaction with Anticancer Glycine Derivative of Platinum Complex by Using Spectroscopic Methods and Molecular Docking

In this paper, a new anticancer Pt (II) complex, cis-[Pt (NH3)2(tertpentylgly)]NO3, was synthesized with glycine-derivative ligand and characterized. Cytotoxicity of this water-soluble Pt complex was studied against human cancer breast cell line of MCF-7. The interaction of human serum albumin (HSA) with Pt complex was studied by using UV-Vis, fluorescence spectroscopy methods, and molecular docking at 27 and 37?°C in the physiological situation (I = 10?mM, pH = 7.4). The negative ΔHb0 and positive ΔSb0 indicated that electrostatic force may be a major mode in the binding between Pt complex and HSA. Binding constant values were obtained through UV-Vis and fluorescence spectroscopy that reveal strong interaction. The negative Gibbs free energy that was obtained by using the UV-Vis method offers spontaneous interaction. Fluorescence quenching the intensity of HSA by adding Pt complex confirms the static mode of interaction is effective for this binding process. Hill coefficients, nH, Hill constant, kH, complex aggregation number around HSA, , number of binding sites, g, HSA melting temperature, Tm, and Stern-Volmer constant, kSV, were also obtained. The kinetics of the interaction was studied, which showed a second-order kinetic. The results of molecular docking demonstrate the position of binding of Pt complex on HSA is the site I in the subdomain IIA.

Palladium and platinum complexes of folic acid as new drug delivery systems for treatment of breast cancer cells

Cisplatin is administrated as an agent in treatment of various cancers by intercalation between DNA strands and inhibition of DNA replication. Among the various factors, two important reasons like inhibition of apoptosis by anti-apoptotic mechanisms and i

Synthesis, characterization and anticancer evaluation of transplatin derivatives with heterocyclic thiones

Platinum(II) complexes of heterocyclic thiones (L) based on transplatin having the general formula, trans-[Pt(NH3)2(Thione)2](NO3)2 have been synthesized and characterized using elemental analysis, IR, and NMR (1H & 13C) spectroscopy. The crystal structures of two of them, trans-[Pt(NH3)2(Imt)2](NO3)2 (1) and trans-[Pt(NH3)2(Me2Imt)2](NO3)2 (3) were determined by X-ray crystallography. The structures of 1 and 3 consist of trans-[Pt(NH3)2L2]2+ complex ions and nitrate counter ions. The platinum atom in both the complex ions adopts a distorted square planar geometry. The spectroscopic data indicated the coordination of thione ligands to platinum(II). The in vitro cytotoxicity of these compounds as well as of cisplatin and carboplatin was investigated using MTT assay against three human cancer cell lines, which are; A549 (lung carcinoma), MCF-7 (breast carcinoma) and HTC15 (colon cancer). The in vitro cytotoxicity in several cases is comparable or even higher, than carboplatin and in two cases than cisplatin.

Exploring the DNA binding/cleavage, cellular accumulation and topoisomerase inhibition of 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinone Mannich bases and their platinum(II) complexes

Several chlorido and amino Pt2 + complexes of 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinone Mannich bases HL exhibiting moderate to high cytotoxicity against cancer cell lines were studied in order to investigate their modes of DNA binding, in vitro DNA strand breaks, mechanism of topoisomerase (Topo I) inhibition and cellular accumulation. DNA model base studies have shown that complex 1a [Pt(HL1)Cl2] was capable of binding covalently to 9-ethylguanine (9-EtG) and 5′-GMP. 1H NMR and mass spectrometry studies have shown that both chlorides were substituted by 9-EtG ligands, whereas 5′-GMP was able to replace only one chlorido ligand, due to steric hindrance. The chlorido Pt2 + complexes [Pt(HL)Cl2] highly accumulate in prostate (PC-3) and melanoma (MDA-MB-435) cell lines, being able to induce DNA strand breaks in vitro and inhibit Topo I by a catalytic mode. On the other hand, the free 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinones HL and the amino Pt2 + complexes [Pt(L-)(NH3)2]NO3 neither cause DNA strand breakage nor exhibit strong DNA interaction, nevertheless the latter were also found to be catalytic inhibitors of Topo I at 100 μM. Thus, coordination of the Mannich bases HL to the PtCl2 fragment substantially affects the chemical and biophysical properties of the pro-ligands, leading to an improvement of their DNA binding properties and generating compounds that cleave DNA and catalytically inhibit Topo I. Finally, the high cytotoxicity exhibited by the free (uncomplexed) 2-hydroxy-3- (aminomethyl)-1,4-naphthoquinones might be associated with their decomposition in solution, which is not observed for the Pt2 + complexes.

Design, synthesis and anticancer activity of diam(m)ine platinum(II) complexes bearing a small-molecular cell apoptosis inducer dichloroacetate

Four new diam(m)ine platinum complexes containing the dichloroacetate moiety in 3-dichoroacetoxylcyclobutane-1,1-dicarboxylate as the leaving group were synthesized, characterized by elemental analysis as well as by ESI+-MS (electrospray ionization mass spectrometry in positive mode), FT-IR, 1H- and 13C-NMR, and evaluated for their in vitro anticancer activity against human lung cancer cell line (A549) and ovarian cancer cell lines (SK-OV-3, SK-OV-3/DDP). Diam(m)ines used in the present study belong to the carriers of six clinically approved platinum drugs. Among the complexes synthesized, complex 2, cis-[Pt(II)(1R,2R-diaminocyclohexane)·(3-dichoroacetoxylcyclobutane-1,1-dicarboxylate)] is the most promising in terms of water solubility and potential of being totally devoid of cross-drug resistance with cisplatin. Therefore, complex 2 was selected for the dichloroacetate release test. The test shows dichloroacetate can be efficiently released from complex 2 under physiological conditions via the hydrolysis of an ester bond bridging the dichloroacetate moiety and platinum pharmacophores together. Our study supports the further evaluation of this complex as a drug candidate.

Unmodified drug used as a material to construct nanoparticles: Delivery of cisplatin for enhanced anti-cancer therapy

The poor solubility of cisplatin (CDDP) often presents a major obstacle in the formulation of CDDP in nanoparticles (NPs) by traditional methods. We have developed a novel method for synthesizing CDDP NPs taking advantage of its poor solubility. By mixing two reverse microemulsions containing KCl and a highly soluble precursor of CDDP, cis-diaminedihydroplatinum (II), we have successfully formulated CDDP NPs with a controllable size (in the range of 12-75 nm) and high drug loading capacity (approximately 80 wt.%). The formulation was done in two steps. The pure CDDP NPs were first stabilized for dispersion in an organic solvent by coating with 1, 2-dioleoyl-sn-glycero-3-phosphate (DOPA). Both x-ray photoelectron spectroscopy and 1H NMR data confirmed that the major ingredient of the DOPA-coated NPs was CDDP. After purification, additional lipids were added to stabilize the NPs for dispersion in an aqueous solution. The final NPs contain a lipid bilayer coating and are named Lipid-Pt-Cl (LPC) NPs, which showed significant antitumor activity both in vitro and in vivo. Thus, CDDP precipitate serves as the major material for assembling the novel NPs. This unique method of nanoparticle synthesis may be applicable in formulating other insoluble drugs.

Maloplatin-B, a Cisplatin-Based BODIPY-Tagged Mito-Specific chemo-PDT Agent Active in Red Light

Maloplatin-B, a cisplatin-based complex, namely [Pt(A-BOD)(NH3)2](NO3) (Pt-A-BOD) with a pendant boron-dipyrromethene (BODIPY) moiety, where HA-BOD is a methyl malonyl chloride derived monostyryl BODIPY ligand, was designed and developed as near-IR light (600-720 nm) organelle-targeting photodynamic therapy agent. The complex [Pt(acac)(NH3)2](NO3) (Pt-Ac) was used as a control. Pt-A-BOD displayed an absorption band at 616 nm (? = 2.9 × 104 M-1 cm-1) in 10% dimethyl sulfoxide/Dulbecco's Modified Eagle's Medium (DMSO/DMEM, pH 7.2). This complex displayed a broad emission band within 650-850 nm with a λem value of 720 nm in 10% DMSO-DMEM (pH 7.2) upon excitation (λex) at 615 nm with a large Stokes shift. The fluorescence quantum yield (φF) value for Pt-A-BOD is 0.032 and for the ligand HA-BOD is 0.24. The BODIPY complex and ligand showed the formation of singlet oxygen as the ROS (reactive oxygen species) on irradiation with near-IR red light of 660 nm, as evidenced from a 1,3-diphenylisobenzofuran (DPBF) assay. The complex displayed remarkable apoptotic NIR light-induced PDT activity with half-maximum inhibitory concentration values (IC50) of 1.6-2.4 μM in A549 lung and HeLa cervical cancer cells, while it was less active in the dark. The cellular ROS generation by the complex in red light was ascertained by a DCFDA (2′,7′-dichlorofluorescein diacetate) assay. Cellular imaging showed its localization primarily in the mitochondria of A549 cancer cells. The JC1 and Annexin-V FITC/PI assays carried out for A549 cancer cells treated with the BODIPY complex showed the alteration of mitochondrial membrane potential and apoptotic cell death on near-IR red light (600-720 nm) irradiation, respectively.